Genentech Pulmozyme recall
Executive Summary
Firm recalls one lot (216,000 ampules) of dornase alfa cystic fibrosis therapy after FDA notes use of unapproved refiltration step to remove metal particulates that entered bulk drug substance after a valve leak. Genentech recalled 23 lots of Pulmozyme in March due to potential packaging defects
You may also be interested in...
Genentech Reorganizing Facility Following FDA Inspection And Warning Letter
Genentech is reorganizing its manufacturing operations in an attempt to address multiple FDA concerns regarding its South San Francisco, Calif., manufacturing facility following an August inspection, the company said.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011